BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25674718)

  • 1. Dose-adjusted EPOCH-R for Burkitt lymphoma.
    Hoelzer D
    Clin Adv Hematol Oncol; 2014 Nov; 12(11):777-9. PubMed ID: 25674718
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose-adjusted EPOCH-R: a feasible alternative for Burkitt lymphoma in resource-constrained settings.
    Jindal N; Jain A; Lad D; Prakash G; Khadwal A; Malhotra P
    Br J Haematol; 2020 Sep; 190(6):e362-e363. PubMed ID: 32614462
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
    Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
    Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rare cause of gastric malignancy: Burkitt's lymphoma.
    Doycheva I; Tanner S; Zhou D; Samadder NJ
    Endoscopy; 2013; 45 Suppl 2 UCTN():E432-3. PubMed ID: 24338176
    [No Abstract]   [Full Text] [Related]  

  • 5. Conventional dose intensive immunochemotherapy regimen in an adult patient with very late relapse of Burkitt's lymphoma.
    Italiano A; Peyrade F; Soler C; Cardot N; Thyss A
    J Chemother; 2007 Apr; 19(2):236-8. PubMed ID: 17434838
    [No Abstract]   [Full Text] [Related]  

  • 6. DA-EPOCH-R in Burkitt Lymphoma: Is It Enough for High-Risk Disease?
    Hertzberg M; Joske DJL; Gandhi MK
    J Clin Oncol; 2020 Nov; 38(31):3722-3723. PubMed ID: 32931401
    [No Abstract]   [Full Text] [Related]  

  • 7. Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?
    Lim KJC; Filshie R
    Lancet Haematol; 2023 Dec; 10(12):e942-e943. PubMed ID: 37922924
    [No Abstract]   [Full Text] [Related]  

  • 8. New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma.
    Frick M; Dörken B; Lenz G
    Best Pract Res Clin Haematol; 2012 Mar; 25(1):3-12. PubMed ID: 22409819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of HIV-Associated Lymphomas: The Latest Approaches for Optimizing Outcomes.
    Hunter NB; Vogt S; Ambinder RF
    Oncology (Williston Park); 2017 Dec; 31(12):872-7, 884. PubMed ID: 29297171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
    Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
    Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burkitt lymphomas failing dose-adjusted R-EPOCH (DA-R-EPOCH).
    Aurer I; Bašić-Kinda S; Radman I; Ilić I; Grah JJ
    Ann Hematol; 2014 Jan; 93(1):177-8. PubMed ID: 23636314
    [No Abstract]   [Full Text] [Related]  

  • 12. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma: report of a case in the oral cavity.
    Jaradat JM; Potluri A; Bilodeau EA
    Indian J Dent Res; 2013; 24(3):384-6. PubMed ID: 24025890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of progression during reductive prophase for paediatric primary mediastinal B-cell lymphoma using dose-adjusted EPOCH chemotherapy.
    Chen RL; Chuang SS; Lu YH
    Pediatr Blood Cancer; 2011 Jul; 56(7):1149-50. PubMed ID: 21337677
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of Burkitt lymphoma and Burkitt-like lymphoma].
    Maruyama D
    Rinsho Ketsueki; 2011 Oct; 52(10):1645-54. PubMed ID: 21971242
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma.
    Crosswell HE; Bergsagel DJ; Yost R; Lew G
    Pediatr Blood Cancer; 2008 Apr; 50(4):883-5. PubMed ID: 17278123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [How to improve the efficacy of R-CHOP for indolent B-cell lymphoma?].
    Tobinai K
    Rinsho Ketsueki; 2012 Jun; 53(6):609-17. PubMed ID: 22790636
    [No Abstract]   [Full Text] [Related]  

  • 17. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.
    Chihara D; Westin JR; Miranda RN; Cheah CY; Oki Y; Turturro F; Romaguera JE; Neelapu SS; Nastoupil LJ; Fayad LE; Rodriguez MA; Fowler NH; Orlowski RZ; Wang M; Hagemeister FB; Medeiros LJ; Fanale MA
    Br J Haematol; 2017 Nov; 179(3):503-506. PubMed ID: 27378601
    [No Abstract]   [Full Text] [Related]  

  • 18. AIDS-lymphoma (ARL): one more step along the way.
    Levine AM
    Blood; 2013 Nov; 122(19):3244-6. PubMed ID: 24203926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.
    Chihara D; Fowler NH; Oki Y; Fanale MA; Fayad LE; Westin JR; Hagemeister FB
    Br J Haematol; 2017 Dec; 179(5):851-854. PubMed ID: 27502933
    [No Abstract]   [Full Text] [Related]  

  • 20. R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma.
    Fowler NH
    Clin Adv Hematol Oncol; 2014 Sep; 12(9):608-10. PubMed ID: 25654483
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.